Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended ...

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Pasithea Therapeutics Corp ( ($KTTA) ) has shared an update. On November 28, 2025, Pasithea Therapeutics Corp announced a public offering of ...

Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson ...

Pasithea Therapeutics Corp (NASDAQ: KTTA) shares are trading sharply higher Wednesday following a string of upbeat updates.

The human body experiences various health problems because of inflammation, which can lead to joint pain, heart disease and ...

Detailed price information for Pasithea Therapeutics Corp (KTTA-Q) from The Globe and Mail including charting and trades.

Robust balance sheet with cash, cash equivalents, and marketable securities of $362 million as of September 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Nov. 12, 2025 (GLOBE ...

Erasca, Inc. (NASDAQ:ERAS) is one of the 12 hot penny stocks to invest in right now. On November 14, 2025, Erasca, Inc.

The University of Michigan's consumer sentiment index edged higher to 51.0 in November versus a preliminary reading of 50.3.